News >

ALK Inhibitors Continue to Reshape Treatment in NSCLC

Danielle Bucco
Published: Monday, Feb 19, 2018

Ravi Salgia, MD, PhD

Ravi Salgia, MD, PhD
It is an exciting time in the treatment landscape of ALK-positive non–small cell lung cancer (NSCLC), as there have been a number of regulatory decisions and clinical trial findings with regard to ALK-specific tyrosine kinase inhibitors (TKIs), explains Ravi Salgia, MD, PhD.

-directed therapies for patients with NSCLC.

OncLive: Can you speak to how newer ALK inhibitors are being developed to counter resistance?

Salgia: I discussed many ALK trials in NSCLC. I was one of the physicians involved in bringing crizotinib to fruition. When we designed the clinical trial initially, that was the compound known as PF02341066. Based on that, it was supposed to be a MET inhibitor, which it is, but then we also realized with our colleagues that it was an ALK inhibitor. That is how the phase I clinical trial was done that was published in the New England Journal of Medicine. Ultimately, it became FDA approved because there was such a strong progression-free survival (PFS)—even in third-line, fourth-line, and fifth-line therapies—with crizotinib. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x